New drug targets inflammation in Hard-to-Treat Behçet's disease
Disease control
Terminated
This trial tests a drug called ivarmacitinib in people with Behçet's disease who have not improved with standard treatments. Ivarmacitinib blocks a key inflammation pathway (JAK-STAT) to reduce symptoms. Participants take the drug daily for 24 weeks, and researchers monitor their…
Phase: PHASE2 • Sponsor: Liu Tian • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC